Is Asiminib useful for chronic myelogenous leukemia?

Chronic myeloid leukemia (CML) is a malignant tumor that affects the blood and bone marrow. It is characterized by the production of a large number of immature white blood cells that accumulate in the bone marrow and inhibit the normal hematopoietic function of the bone marrow. In recent years, aceminib, as a new therapeutic drug, has achieved remarkable results in the treatment of CML.

Asiminib is the first BCR::ABL1 inhibitor that specifically targets the ABLmyristoyl pocket (STAMP ). Unlike traditional tyrosine kinase inhibitors (TKIs), it specifically binds to the myristoyl pocket of ABL. Effectively inhibiting BCR-ABL1 cancer protein kinase activity provides a new way to solve CML drug resistance problems in patients.

In clinical trials, Aceminib has demonstrated significant efficacy. For example, in the ASCEMBL study, patients who had previously received ≥2TKIstreated CML patients, the major molecular response (MMR) rate in the aciminib treatment group was significantly higher than that in the control group. During several years of follow-up, the sustained efficacy of aceminib has also been verified, indicating that it has a long-term control effect on CML.

In addition to its remarkable efficacy, Aceminib also performs well in terms of safety and tolerability. Although patients may experience some adverse reactions, such as upper respiratory tract infection, musculoskeletal pain, etc., most can be controlled with appropriate medical management. Compared with traditional TKIs, aceminib has a relatively lower incidence of side effects, allowing patients to better tolerate the treatment.

Aximini’s excellent efficacy and safety makeCMLPatient outcomes improved significantly. With treatment, patients can achieve longer survival and better quality of life. In addition, aceminib provides a new treatment option for patients who have developed resistance to other treatments.